Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Brain Metastases from NSCLC

Lung Cancer; ePub 2016 Apr 6; Hsu, et al

Publish date:: April 19, 2016

There is a higher incidence of brain metastases for patients with EGFR+ metastatic non-small cell lung cancer (NSCLC), even when adjusted for differences in survival, compared to EGFR wild type (WT). This according to a study of 541 patients with NSCLC, including 121 with EGFR+ and 422 with EGFR WT. Researchers found:

• Cumulative incidence of brain metastases was 39.2% for patients with EGFR+ vs 28.2% for EGFR WT.

• In multivariate analysis, younger age and EGFR+ status were significant factors for developing brain metastases.

• Median survival for the EGFR+ cohort was 22.4 months vs 7.9 months for the EGFR WT cohort.

• In multivariate analysis, poor performance status and brain metastases were factors significant for worse survival.

Citation: Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer. [Published online ahead of print April 6, 2016]. Lung Cancer. doi:10.1016/j.lungcan.2016.04.004.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,